The main goal of this study is to redirect T-cell specificity toward CD123 via CAR to target AML and to generate preclinical data in support of an adoptive immunotherapy trial using this novel CAR for both AML and B-ALL. The gene discussed is IL3RA; the disease is acute lymphoblastic leukemia.